Global

CN EN
  1. HOME
  2. ABOUT US
    About Laekna Core Management Team Board of Directors Milestones Scientific Advisory Board Core Investors Honors & Awards
  3. R&D
    R&D Therapeutic Areas Candidates Pipeline Clinical Trials
  4. PARTNERSHIPS
    Strategic Partners Business Development Holistic Approach BD Contact
  5. INVESTORS
    Corporate Governance Financial Results Announcements and Circulars IR Calendar Listing Documents
  6. NEWS
    Press Releases Media Coverage
  7. CAREERS
    Global Team Career Development Jobs My Laekna
  8. CONTACT US
    Contact Us Leave Message
  9. RSS Feeds
 ABOUT US
GROUND-BREAKING THERAPEUTICS

Founded in 2016,

we are a clinical-stage biotechnology company

Learn More
Operation Team
Research & Development Team
in China and the US
 ABOUT US
GROUND-BREAKING THERAPEUTICS

Founded in 2016,

we are a clinical-stage biotechnology company

Learn More
Research & Development Team
in China and the US
Zhangjiang Pharma Valley, Shanghai, China
New Jersey, USA
Operation Team
Lingang, Shanghai
R&D
LEADING INNOVATION

Committed to bringing

novel therapies to

patients with cancer, metabolic diseases

and liver fibrosis

More in the pipeline

  1. 20

    projects in

    our pipeline


  2. 7

    clinical

    trials

  3. including3

    multi-regional clinical trials

    (MRCTs)

  4. including1

    phase III pivotal

    clinical trial

NEWS
LATEST ARTICLES
Learn More
  1. 2024-11-20
    Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
    More
  2. 2024-10-16
    Laekna Initiated SC Cohort in the Phase I SAD Study of LAE102 for The Treatment of Obesity
    More
  3. 2024-09-19
    Laekna Announces Robust Phase 1b data of LAE002 (afuresertib) for treatment of HR+/ HER2- Breast Cancer at ESMO Congress 2024
    Learn More
    2024-08-19
    Laekna (2105.HK) Announces Interim Results 2024
    Learn More
NEWS
LATEST ARTICLES
Learn More
  1. 2024-11-20
    Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
    More
  2. 2024-10-16
    Laekna Initiated SC Cohort in the Phase I SAD Study of LAE102 for The Treatment of Obesity
    More
  3. 2024-09-19
    Laekna Announces Robust Phase 1b data of LAE002 (afuresertib) for treatment of HR+/ HER2- Breast Cancer at ESMO Congress 2024
    More
CAREERS
OUR PEOPLE
Join Us
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin

  1. HOME
  2. ABOUT US
  3. R&D
  4. PARTNERSHIPS
  5. INVESTORS
  6. NEWS
  7. CAREERS
  8. CONTACT US

Copyright © Laekna Therapeutics, All Rights Reserved.  沪ICP备17047795号 Privacy Policy

Follow us on Linkedin

Follow us on Wechat